Fatty acids and insulin resistance in muscle and liver

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 19, Issue 4, 2005, Pages 625-635

  Kovacs, Peter ^a   Stumvoll, Michael ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Free fatty acids; Hepatocellular lipids; Insulin resistance; Intramyocellular lipids; Lipolysis; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; FATTY ACID DERIVATIVE; GLUCOSE 6 PHOSPHATE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; ROSIGLITAZONE; TRANSCRIPTION FACTOR; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

DRUG RECEPTOR BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HEART MUSCLE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID LIVER LEVEL; LIPID STORAGE; LIVER CELL; MUSCLE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRIENT; OBESITY; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

DIABETES MELLITUS, TYPE 2; FATTY ACIDS; GLUCOSE; HUMANS; INSULIN RESISTANCE; LIPIDS; LIVER; MUSCLE, SKELETAL; OBESITY; THIAZOLIDINEDIONES;

EID: 29244462992     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2005.07.003     Document Type: Review

References (98)

1. E. Kraegen & G.J. Cooney The role of free fatty acids in muscle insulin resistance In S. Marshall P. Home & R. Rizza (eds.) The Diabetes Annual 1999 Elsevier Amsterdam 141-160
2. S.W. Coppack M.D. Jensen & J.M. Miles In vivo regulation of lipolysis in humans Journal of Lipid Research 35 1994 177-193
3. G. Boden & G.I. Shulman Free fatty acids in obesity and type 2 diabetes: Defining their role in the development of insulin resistance and beta-cell dysfunction European Journal of Clinical Investigation 32 supplement 3 2002 14-23
4. D.E. Moller & J.S. Flier Insulin resistance - mechanisms, syndromes, and implications The New England Journal of Medicine 325 1991 938-948
5. W.T. Garvey & M.J. Birnbaum Cellular insulin action and insulin resistance Baillieres Clinical Endocrinology and Metabolism 7 1993 785-873
6. H. Yki-Järvinen Pathogenesis of non-insulin-dependent diabetes mellitus Lancet 343 1994 91-95
7. M. Stumvoll & S. Jacob Multiple sites of insulin resistance: Muscle, liver and adipose tissue Experimental and Clinical Endocrinology and Diabetes 107 1999 107-110
8. C.T. Montague & S. O'Rahilly The perils of portliness: Causes and consequences of visceral adiposity Diabetes 49 2000 883-888
9. P.J. Randle P.B. Garland C.N. Hales & E.A. Newsholme The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus Lancet 1 1963 785-789
10. D. Thiebaud R.A. DeFronzo E. Jacot et al. Effect of long chain triglyceride infusion on glucose metabolism in man Metabolism 31 1982 1128-1136
11. E. Ferrannini E.J. Barrett S. Bevilacqua & R.A. DeFronzo Effect of fatty acids on glucose production and utilization in man Journal of Clinical Investigation 72 1983 1737-1747
12. D.E. Kelley M. Mokan J.A. Simoneau & L.J. Mandarino Interaction between glucose and free fatty acid metabolism in human skeletal muscle Journal of Clinical Investigation 92 1993 91-98
13. H. Yki-Jarvinen I. Puhakainen & V.A. Koivisto Effect of free fatty acids on glucose uptake and nonoxidative glycolysis across human forearm tissues in the basal state and during insulin stimulation Journal of Clinical Endocrinology and Metabolism 72 1991 1268-1277
14. M. Roden T.B. Price G. Perseghin et al. Mechanism of free fatty acid-induced insulin resistance in humans Journal of Clinical Investigation 97 1996 2859-2865
15. B.M. Wolfe S. Klein E.J. Peters et al. Effect of elevated free fatty acids on glucose oxidation in normal humans Metabolism 37 1988 323-329
16. S. Bevilacqua R. Bonadonna G. Buzzigoli et al. Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects Metabolism 36 1987 502-506
17. S. Bevilacqua G. Buzzigoli R. Bonadonna et al. Operation of Randle's cycle in patients with NIDDM Diabetes 39 1990 383-389
18. G. Boden X. Chen J. Ruiz et al. Mechanisms of fatty acid-induced inhibition of glucose uptake Journal of Clinical Investigation 93 1994 2438-2446
19. G. Boden F. Jadali J. White et al. Effects of fat on insulin-stimulated carbohydrate metabolism in normal men Journal of Clinical Investigation 88 1991 960-966
20. A. Dresner D. Laurent M. Marcucci et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity Journal of Clinical Investigation 103 1999 253-259
21. G.I. Shulman Cellular mechanisms of insulin resistance Journal of Clinical Investigation 106 2000 171-176
22. M. Hawkins N. Barzilai R. Liu et al. Role of the glucosamine pathway in fat-induced insulin resistance Journal of Clinical Investigation 99 1997 2173-2182
23. B.J. Goldstein F. Ahmad W. Ding et al. Regulation of the insulin signalling pathway by cellular protein-tyrosine phosphatases Molecular and Cellular Biochemistry 182 1998 91-99
24. M. Stumvoll C. Meyer A. Mitrakou et al. Renal glucose production and utilization: New aspects in humans Diabetologia 40 1997 749-757
25. M. Stumvoll B.J. Goldstein & T.W. van Haeften Type 2 diabetes: principles of pathogenesis and therapy Lancet 365 2005 1333-1346
26. R.A. DeFronzo E. Ferrannini R. Hendler et al. Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange Proceedings of the National Academy of Sciences of the United States of America 75 1978 5173-5177
27. R.A. DeFronzo Lilly lecture 1987. The triumvirate: Beta-cell, muscle, liver. A collusion responsible for NIDDM Diabetes 37 1988 667-687
28. R.A. DeFronzo Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis Netherlands Journal of Medicine 50 1997 191-197
29. E. Ferrannini D.C. Simonson L.D. Katz et al. The disposal of an oral glucose load in patients with non-insulin-dependent diabetes Metabolism 37 1988 79-85
30. R.A. DeFronzo E. Ferrannini R. Hendler et al. Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man Diabetes 32 1983 35-45
31. A.D. Cherrington Banting lecture 1997. Control of glucose uptake and release by the liver in vivo Diabetes 48 1999 1198-1214
32. K. Rebrin G.M. Steil L. Getty & R.N. Bergman Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin Diabetes 44 1995 1038-1045
33. C. Saloranta V. Koivisto E. Widen et al. Contribution of muscle and liver to glucose-fatty acid cycle in humans American Journal of Physiology 264 1993 E599-E605
34. D.K. Sindelar C.A. Chu M. Rohlie et al. The role of fatty acids in mediating the effects of peripheral insulin on hepatic glucose production in the conscious dog Diabetes 46 1997 187-196
35. X. Chen N. Iqbal & G. Boden The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects Journal of Clinical Investigation 103 1999 365-372
36. G. Boden X. Chen E. Capulong & M. Mozzoli Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes Diabetes 50 2001 810-816
37. G.R. Fulcher M. Walker C. Catalano et al. Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects Diabetes 41 1992 1400-1408
38. D. Worm J.E. Henriksen A. Vaag et al. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period Journal of Clinical Endocrinology and Metabolism 78 1994 717-721
39. A. Vaag P. Skott P. Damsbo et al. Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus Journal of Clinical Investigation 88 1991 1282-1290
40. I. Puhakainen & H. Yki-Jarvinen Inhibition of lipolysis decreases lipid oxidation and gluconeogenesis from lactate but not fasting hyperglycemia or total hepatic glucose production in NIDDM Diabetes 42 1993 1694-1699
41. G. Boden Role of fatty acids in the pathogenesis of insulin resistance and NIDDM Diabetes 46 1997 3-10
42. G. Boden P. Cheung T.P. Stein et al. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis American Journal of Physiology Endocrinology and Metabolism 283 2002 E12-E19
43. T.K. Lam H. Yoshii C.A. Haber et al. Free fatty acid-induced hepatic insulin resistance: A potential role for protein kinase C-delta American Journal of Physiology Endocrinology and Metabolism 283 2002 E682-E691
44. H. Bays L. Mandarino & R.A. DeFronzo Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: Peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach Journal of Clinical Endocrinology and Metabolism 89 2004 463-478
45. J.J. Bahl M. Matsuda R.A. DeFronzo & R. Bressler In vitro and in vivo suppression of gluconeogenesis by inhibition of pyruvate carboxylase Biochemical Pharmacology 53 1997 67-74
46. J.R. Williamson R.A. Kreisberg & P.W. Felts Mechanism for the stimulation of gluconeogenesis by fatty acids in perfused rat liver Proceedings of the National Academy of Sciences of the United States of America 56 1966 247-254
47. D. Massillon N. Barzilai M. Hawkins et al. Induction of hepatic glucose-6-phosphatase gene expression by lipid infusion Diabetes 46 1997 153-157
48. K. de Fea & R.A. Roth Protein kinase C modulation of insulin receptor substrate-1 tyrosine phosphorylation requires serine 612 Biochemistry 36 1997 12939-12947
49. L.V. Ravichandran D.L. Esposito J. Chen & M.J. Quon Protein kinase C-zeta phosphorylates insulin receptor substrate-1 and impairs its ability to activate phosphatidylinositol 3-kinase in response to insulin Journal of Biological Chemistry 276 2001 3543-3549
50. N.J. Faergeman & J. Knudsen Role of long-chain fatty acyl-CoA esters in the regulation of metabolism and in cell signalling The Biochemical Journal 323 1997 1-12
51. Y.T. Kruszynska D.S. Worrall J. Ofrecio et al. Fatty acid-induced insulin resistance: Decreased muscle PI3K activation but unchanged Akt phosphorylation Journal of Clinical Endocrinology and Metabolism 87 2002 226-234
52. S. Kashyap R. Belfort J. Finlayson et al. A chronic physiologic increase in FFA in healthy subjects causes insulin signaling defects similar to those of insulin-resistant non-diabetic subjects with a strong family history of T2DM Diabetes 51 supplement 2 2002 A24
53. T.K. Lam A. Carpentier G.F. Lewis et al. Mechanisms of the free fatty acid-induced increase in hepatic glucose production American Jouranl of Physiology Endocrinology and Metabolism 284 2003 E863-E873
54. J.K. Kim J.J. Fillmore Y. Chen et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance Proceedings of the National Academy of Sciences of the United States of America 98 2001 7522-7527
55. M. Krssak & M. Roden The role of lipid accumulation in liver and muscle for insulin resistance and type 2 diabetes mellitus in humans Reviews in Endocrine and Metabolic Disorders 5 2004 127-134
56. M. Krssak K. Falk Petersen A. Dresner et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: A 1H NMR spectroscopy study Diabetologia 42 1999 113-116
57. J. Machann H. Haring F. Schick & M. Stumvoll Intramyocellular lipids and insulin resistance Diabetes Obesity and Metabolism 6 2004 239-248
58. B.H. Goodpaster D.E. Kelley F.L. Thaete et al. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content Journal of Applied Physiology 89 2000 104-110
59. B.H. Goodpaster R. Theriault S.C. Watkins & D.E. Kelley Intramuscular lipid content is increased in obesity and decreased by weight loss Metabolism 49 2000 467-472
60. B.H. Goodpaster J. He S. Watkins & D.E. Kelley Skeletal muscle lipid content and insulin resistance: Evidence for a paradox in endurance-trained athletes Journal of Clinical Endocrinology and Metabolism 86 2001 5755-5761
61. D.A. Pan S. Lillioja A.D. Kriketos et al. Skeletal muscle triglyceride levels are inversely related to insulin action Diabetes 46 1997 983-988
62. K.F. Petersen D. Befroy S. Dufour et al. Mitochondrial dysfunction in the elderly: Possible role in insulin resistance Science 300 2003 1140-1142
63. G. Perseghin P. Scifo F. De Cobelli et al. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: A 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents Diabetes 48 1999 1600-1606
64. G. Perseghin G. Lattuada M. Danna et al. Insulin resistance, intramyocellular lipid content, and plasma adiponectin in patients with type 1 diabetes American Journal of Physiology Endocrinology and Metabolism 285 2003 E1174-E1181
65. R. Sinha S. Dufour K.F. Petersen et al. Assessment of skeletal muscle triglyceride content by (1)H nuclear magnetic resonance spectroscopy in lean and obese adolescents: Relationships to insulin sensitivity, total body fat, and central adiposity Diabetes 51 2002 1022-1027
66. S. Jacob J. Machann K. Rett et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects Diabetes 48 1999 1113-1119
67. A. Kautzky-Willer M. Krssak C. Winzer et al. Increased intramyocellular lipid concentration identifies impaired glucose metabolism in women with previous gestational diabetes Diabetes 52 2003 244-251
68. J.H. Hwang J.W. Pan S. Heydari et al. Regional differences in intramyocellular lipids in humans observed by in vivo 1H-MR spectroscopic imaging Journal of Applied Physiology 90 2001 1267-1274
69. C. Anderwald E. Bernroider M. Krssak et al. Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle Diabetes 51 2002 3025-3032
70. C. Thamer J. Machann O. Bachmann et al. Intramyocellular lipids: anthropometric determinants and relationships with maximal aerobic capacity and insulin sensitivity Journal of Clinical Endocrinology and Metabolism 88 2003 1785-1791
71. A. Virkamaki E. Korsheninnikova A. Seppala-Lindroos et al. Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle Diabetes 50 2001 2337-2343
72. A. Seppala-Lindroos S. Vehkavaara A.M. Hakkinen et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men Journal of Clinical Endocrinology and Metabolism 87 2002 3023-3028
73. M. Tiikkainen M. Tamminen A.M. Hakkinen et al. Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes Obesity Research 10 2002 859-867
74. L. Ryysy A.M. Hakkinen T. Goto et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients Diabetes 49 2000 749-758
75. D.E. Kelley T.M. McKolanis R.A. Hegazi et al. Fatty liver in type 2 diabetes mellitus: Relation to regional adiposity, fatty acids, and insulin resistance American Journal of Physiology Endocrinology and Metablism 285 2003 E906-E916
76. K.F. Petersen E.A. Oral S. Dufour et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy Journal of Clinical Investigation 109 2002 1345-1350
77. J. Sutinen A.M. Hakkinen J. Westerbacka et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy AIDS 16 2002 2183-2193
78. G. Marchesini M. Brizi G. Bianchi et al. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome Diabetes 50 2001 1844-1850
79. M. Sargin O. Uygur-Bayramicli H. Sargin et al. Association of nonalcoholic fatty liver disease with insulin resistance: Is OGTT indicated in nonalcoholic fatty liver disease? Journal of Clinical Gastroenterology 37 2003 399-402
80. A.B. Mayerson R.S. Hundal S. Dufour et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes Diabetes 51 2002 797-802
81. M. Bajaj S. Suraamornkul T. Pratipanawatr et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes Diabetes 52 2003 1364-1370
82. D.G. Carey G.J. Cowin G.J. Galloway et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients Obesity Research 10 2002 1008-1015
83. K. Schoonjans & J. Auwerx Thiazolidinediones: An update Lancet 355 2000 1008-1010
84. J.M. Olefsky Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists Journal of Clinical Investigation 106 2000 467-472
85. S. Matthaei M. Stumvoll M. Kellerer & H.U. Häring Pathophysiology and pharmacological treatment of insulin resistance Endocrine Reviews 21 2000 585-618
86. M. Stumvoll & H.U. Haring Glitazones: Clinical effects and molecular mechanisms Annals of Medicine 34 2002 217-224
87. E. Murphy & J.J. Nolan Insulin sensitiser drugs Expert Opinion on Investigational Drugs 9 2000 1347-1361
88. C. Hofmann K. Lorenz S.S. Braithwaite et al. Altered gene expression for tumor necrosis factor-α and its receptor during drug and dietary modulation of insulin resistance Endocrinology 134 1994 264-270
89. C.M. Steppan S.T. Bailey S. Bhat et al. The hormone resistin links obesity to diabetes Nature 409 2001 307-312
90. P. De Vos A.M. Lefebvre S.G. Miller et al. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma Journal of Clinical Investigation 98 1996 1004-1009
91. C.B. Kallen & M.A. Lazar Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes Proceedings of the National Academy of Sciences of the United States of America 93 1996 5793-5796
92. N. Maeda M. Takahashi T. Funahashi et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein Diabetes 50 2001 2094-2099
93. T. Yamauchi J. Kamon H. Waki et al. The mechanisms by which both heterozygous PPARgamma deficiency and PPARgamma agonist improve insulin resistance Journal of Biological Chemistry 276 2001 41245-41254
94. M. Adams C.T. Montague J.B. Prins et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation Journal of Clinical Investigation 100 1997 3149-3153
95. Y. Mori Y. Murakawa K. Okada et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients Diabetic Care 22 1999 908-912
96. S. Akazawa F. Sun M. Ito et al. Efficacy of troglitazone on body fat distribution in type 2 diabetes Diabetic Care 23 2000 1067-1071
97. Y. Miyazaki A. Mahankali M. Matsuda et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients Journal of Clinical Endocrinology and Metabolism 87 2002 2784-2791
98. Y. Miyazaki L.J. Hardies E. Wajcberg et al. Effect of piolgitazone on liver fat content, abdominal fat distribution, and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM) Diabetes 51 supplement 2 2002 A69